Overview

Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy

Status:
Active, not recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

The aim of the ProCAID study is to determine if the addition of the AKT inhibitor AZD5363 to docetaxel and prednisolone (DP) prolongs progression free survival (PFS) in Metastatic castration resistant prostate cancer to a degree worthy of further investigation

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University Hospital Southampton NHS Foundation Trust

Collaborators:

AstraZeneca
Cancer Research UK

Treatments:

Docetaxel
Prednisolone